ALS veteran backs Proposition 38 in new ad
San Diego-area Air Force veteran Jessy Ybarra appears in a new video ad supporting Proposition 38, a California ballot measure aimed at boosting medical research funding. The proposal would direct $8.4 billion toward immunology research and related treatments for diseases including ALS, cancer and Alzheimer’s.
Why it matters: - Proposition 38 would create a new funding stream for medical research tied to diseases that affect millions of patients, including ALS, cancer, Alzheimer’s, heart disease and other chronic conditions. - Supporters say the measure could speed up treatments and breakthroughs at a time when federal research cuts are slowing clinical trials and discoveries. - For people living with ALS, the measure is framed as a race against time because the disease steadily takes away the ability to walk, talk, eat, use their hands and eventually breathe.
What happened: - Jessy Ybarra, a San Diego-area U.S. Air Force veteran living with ALS and a member of the ALS Association Board of Trustees, appears in a new video advertisement backing YES on Proposition 38. - Ybarra also shared his message in an October 1 guest opinion in the San Diego Union-Tribune. - Ybarra was diagnosed with ALS in 2017 after four years in the U.S. Air Force and 32 years in information technology. - Ybarra says he hopes medical research advances will help him live long enough to see his son and granddaughter graduate from college. - The campaign is promoting Proposition 38 as the Immunology Medical Research & Cures Initiative.
The details: - The measure would direct $8.4 billion toward immunology research to help cure and prevent cancer, Alzheimer’s, heart disease and other persistent diseases. - Supporters say immunotherapies already treat patients with melanoma, lung cancer, leukemia and lymphoma. - Proposition 38 would also fund research into Parkinson’s, diabetes, ALS, muscular dystrophy, rheumatoid arthritis, lupus and multiple sclerosis. - The proposal would split funding evenly, with half going to competitive grants at California universities and nonprofit research institutions. - The other half would support a nonprofit immunology institute affiliated with the University of California to connect scientists, technology, laboratories, patients and clinical trials. - The measure is designed to pay for itself. - Ten percent of proceeds from licensing immunotherapies developed under the measure would return to California to offset total costs, including interest. - Any cure or immunotherapy developed under the measure would be provided to California patients at a 20% discount below the national average. - The initiative includes a 2% cap on state administrative expenses. - The measure requires public disclosure of spending and independent financial audits. - For-profit corporations would not be eligible for grant funding.
Between the lines: - The campaign is pairing a personal ALS story with a broader argument that California can step in as federal support becomes less certain. - Ybarra’s message is designed to make the funding debate personal by focusing on milestones his family may reach only if research moves faster. - The measure’s structure signals an attempt to answer likely criticism about cost, oversight and whether the money would reach patients quickly. - Melanie Lendnal, executive vice president and chief of advocacy at the ALS Association, said emerging insights from immunology are reshaping how ALS is understood and where treatments may come from. - Lendnal said Proposition 38 is a critical step toward accelerating research that could slow disease progression.
What’s next: - Supporters are directing voters to YESon38.com for a coalition list and additional statements from backers. - The campaign is also using social media channels on LinkedIn, Instagram, Facebook, X and Substack. - The measure’s fate now depends on voter support in California.
The bottom line: - Proposition 38 is being sold as both a research investment and a personal urgency play: more money for immunology science, and potentially more time for patients like Jessy Ybarra.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Fintech World Post
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.